Samsung Biologics nears $2 billion takeover of PolyPeptide
The deal would hand the Korean contract manufacturer one of the largest dedicated peptide API producers serving incretin and other peptide drug programs.
TR
By Tom Reyes · Markets Editor
Oct 13 21:09 ETSource: Businesskorea
The wire
- 01Businesskorea reports Samsung Biologics is close to acquiring peptide manufacturer PolyPeptide in a transaction valued at about $2 billion.
- 02Peptide API capacity is the bottleneck behind incretin and specialty peptide supply, so ownership changes at a major producer affect contract availability and pricing for drugmakers.
- 03Terms and timing have not been confirmed by the companies, and any deal of this size would face regulatory clearances before closing.
From the source
Read at businesskorea.co.krSamsung Biologics Nears $2 Billion PolyPeptide Takeover
